CD274 and neoplasm: After treatment with pembrolizumab, melanoma cells released EVs enriched in PD-L1, which suppresses the proliferation of cytotoxic T cells and facilitates the immune evasion of tumor cells, counteracting the efficacy of pembrolizumab.